Skip to main content

Table 1 Patient characteristics (n = 188)

From: Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix

Parameters

No. (%)

Mean ± SEM

Age (years)

 

56.5 ± 0.8

Stage

  

   I

22 (11.7%)

 

   II

125 (66.5%)

 

   III

37 (19.7%)

 

   IV

4 (2.1%)

 

Smoking

  

   No

173 (92.0%)

 

   Yes

15 (8.0%)

 

Pelvic lymphadenopathy on CT scan

  

   No

167 (88.8%)

 

   Yes

21 (11.2%)

 

Parametrial scores

  

   0

36 (19.1%)

 

   1-3

103 (54.8%)

 

   4-6

49 (26.1%)

 

Hemoglobin (g/dL)

 

11.1 ± 0.2

Field size (Y-axis) (cm)

 

18.3 ± 0.1

HDR dose to point A (Gy)

 

24.3 ± 0.2

RT duration (days)

 

61.2 ± 1.1

Pretreatment SCC-Ag level (ng/mL)

 

15.2 ± 2.3

   < 2

60 (31.9%)

 

   2-10

68 (36.2%)

 

   10-20

21 (11.6%)

 

   20-40

21 (11.6%)

 

   ≥ 40

18 (9.6%)

 

Pretreatment CEA level (ng/mL)

 

7.7 ± 1.7

   < 5

149 (79.3%)

 

   5-10

16 (8.5%)

 

   ≥ 10

23 (12.2%)

 

EBRT technique

  

   AP/PA

2 (1.1%)

 

   Four-field

174 (92.6%)

 

   IMRT

12 (6.4%)

 

EBRT dose (Gy)

  

   Central dose

 

42.2 ± 0.3

   Parametrial dose

 

47.2 ± 0.4